Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 386 + FOLFIRI in metastatic colorectal cancer
NCT00752570Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2008
- Primary completion
- Sep 2010
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
01
Overview
Phase 2, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing AMG 386 + FOLFIRI with Placebo + FOLFIRI (2 arms). Primary endpoint: Progression-Free Survival. Started Nov 2008; status: completed.
02
Drugs
trebananib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00752570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00752570.